
Sign up to save your podcasts
Or


In an astonishing story of a scientific discovery, Greg Winter tells Jim Al-Khalili how decades of curiosity-driven research led to a revolution in medicine.
Forced to temporarily abandon his work in the lab when a road rage incident left him with a paralysed right arm, Greg Winter spent several months looking at the structure of proteins. Looking at the stunning computer graphics made the pain in his arm go away. It also led him to a Nobel Prize winning idea: to ‘humanise’ mouse antibodies. A visit to an old lady in hospital made Greg determined to put his research to good use. He fought hard to ensure open access to the technology he invented and set up a start up company to encourage the development of therapeutic drugs. It took years to persuade anyone to fund his Nobel Prize winning idea that led to the creation of an entirely new class of drugs, known as monoclonal antibodies. In 2018, the market for these drugs, which include Humira for rheumatoid arthritis and Herceptin for breast cancer, was worth $70 billion.
By BBC World Service4.4
939939 ratings
In an astonishing story of a scientific discovery, Greg Winter tells Jim Al-Khalili how decades of curiosity-driven research led to a revolution in medicine.
Forced to temporarily abandon his work in the lab when a road rage incident left him with a paralysed right arm, Greg Winter spent several months looking at the structure of proteins. Looking at the stunning computer graphics made the pain in his arm go away. It also led him to a Nobel Prize winning idea: to ‘humanise’ mouse antibodies. A visit to an old lady in hospital made Greg determined to put his research to good use. He fought hard to ensure open access to the technology he invented and set up a start up company to encourage the development of therapeutic drugs. It took years to persuade anyone to fund his Nobel Prize winning idea that led to the creation of an entirely new class of drugs, known as monoclonal antibodies. In 2018, the market for these drugs, which include Humira for rheumatoid arthritis and Herceptin for breast cancer, was worth $70 billion.

7,766 Listeners

1,066 Listeners

5,474 Listeners

1,823 Listeners

971 Listeners

1,799 Listeners

1,049 Listeners

2,071 Listeners

609 Listeners

765 Listeners

89 Listeners

404 Listeners

428 Listeners

825 Listeners

736 Listeners

229 Listeners

333 Listeners

360 Listeners

479 Listeners

243 Listeners

3,224 Listeners

745 Listeners

115 Listeners

1,041 Listeners